News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Link Technologies Ltd Announces Partnership With American International Chemical

5/22/2012 10:55:20 AM

BELLSHILL, SCOTLAND, 22 May 2012: Link Technologies Ltd, an ISO 9001:2008 certified specialist oligonucleotide reagent manufacturer, has announced that it will partner with American International Chemical (AIC) to distribute Link-branded products in North America. AIC will offer a sub-set of Link’s specialist oligonucleotide reagents, focusing on the bulk market for oligonucleotide modifiers. The large-scale purchase of such reagents is of interest to companies who produce large volumes of oligonucleotides for use in life science research and drug discovery.

Link Technologies’ synthesises high quality reagents for DNA, RNA, PNA & UNA synthesis and modification. Initially, AIC will distribute Link’s modified phosphoramidites, including dyes and labels, and CPG solid supports through its Advanced Technology Division. As part of the non-exclusive agreement, Link Technologies will maintain direct contact with existing and new customers in North America at customers’ discretion, and will continue to provide expert technical support to all North American customers.

Dr John Bremner, Business Development Director at Link Technologies, commented: “We are delighted to be working with AIC to expand the availability of our specialist oligonucleotide precursors in the US and Canada. Working at the cutting-edge of nucleotide chemistry, our products are highly regarded for their quality and reliability, and early feedback suggests that customers in North America are enthusiastic about having local access to our portfolio via a well-known and trusted distributor such as AIC. As a manufacturer, though, we know it can be critical for customers to be able to retain contact with us as a key part of the supply-chain, therefore we are still providing that option. It is all about choice.” Ralph Walker, Director, Advanced Technology at AIC, said: “As one of the largest suppliers to the oligonucleotide and phosphoramidite market over the last twenty years, we are dedicated to providing our customers with reagents of the highest possible quality and purity. This new agreement allows us to expand our Advanced Technology product portfolio to include specialist modifiers, and ensures that we can provide our customers with a reliable and consistent supply chain from an internationally renowned source.”

AIC are hosting a booth at this year’s TIDES Oligonucleotide and Peptide Research, Technology and Product Development Meeting in Las Vegas (20-23 May), where it will be showcasing the new product offering (Booth 227). Link’s Technical Manager, Dr Catherine McKeen, will also be at the conference, where she will be sharing her expertise as a panellist during a discussion session entitled ‘The Oligo Supply Chain for Diagnostics - Getting your Research to the Market’ (Wednesday, May 23rd at 11:30 am).

For more information please visit the Link Technologies website at or follow us on Twitter: @linktechdna.

About Link Technologies Ltd

Link Technologies Ltd is a leading kilo-scale supplier of speciality reagents for oligonucleotide synthesis and modification, all to the ISO 9001:2008 quality certification. The company’s main markets are university and commercial research departments, plus, increasingly, larger Contract Manufacturing Organisations (CMOs) in the biotech sector. Link has also forged successful links to academia working closely with many UK universities. In tandem with internal research and development, the Company has an excellent record in bringing in-licence products to market with various worldwide commercial partners.

For further information see:

About AIC

American International Chemical (AIC) is a direct chemical sales and marketing company providing specialty chemicals and biotech chemicals to businesses throughout the United States. AIC's Advanced Technology Division was created in 1985 to support the growing biotechnology, diagnostic and research markets.

For further information see:

Read at

comments powered by Disqus